Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases  Yukinori.

Published byKaarlo Niemi Modified over 5 years ago

Similar presentations

Presentation on theme: "Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases  Yukinori."— Presentation transcript:

1 Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases  Yukinori Sakao, MD, PhD, Sakae Okumura, MD, Mingyon Mun, MD, PhD, Hirofumi Uehara, MD, PhD, Yuichi Ishikawa, MD, PhD, Ken Nakagawa, MD  The Annals of Thoracic Surgery  Volume 89, Issue 4, Pages (April 2010) DOI: /j.athoracsur Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Diagram indicating study group subdivisions. Between 1988 and December 2007, 2,030 patients underwent surgical resections for primary lung cancer at the Cancer Institute Hospital. (PM = intrapulmonary metastases.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Overall 5-year survival rate for multilevel N2 patients (Pt) depends on cN and intrapulmonary metastases (pm). Survival curves were generated using the Kaplan-Meier method. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases  Yukinori."

Similar presentations

Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer  Pierre-Benoit Pagès, MD, Pierre Mordant,

History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer  Pierre-Benoit Pagès, MD, Pierre Mordant,
Primary non-Hodgkin’s lymphoma of the lung

Primary non-Hodgkin’s lymphoma of the lung
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Chun Chieh Lin, PhD, MBA, Matthew P

Chun Chieh Lin, PhD, MBA, Matthew P
Outcomes of Reintervention on the Autograft After Ross Procedure

Outcomes of Reintervention on the Autograft After Ross Procedure
Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer  Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.

Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer  Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.
Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma  Giulio Melloni, MD, Claudio.

Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma  Giulio Melloni, MD, Claudio.
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Similar presentations

Ads by Google